Feeding artery ablation before radiofrequency ablation for hepatocellular carcinoma may reduce critical recurrence.
carcinoma
hepatocellular
radiofrequency ablation
recurrence
ultrasonography
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
28
08
2020
revised:
12
02
2021
accepted:
22
02
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
17
4
2021
Statut:
epublish
Résumé
Percutaneous radiofrequency ablation (RFA) is a minimally invasive and curative local treatment for hepatocellular carcinoma (HCC). However, serious concerns remain regarding critical recurrences such as metastasis, dissemination, and/or seeding due to RFA. In August 2006, we introduced selective feeding artery ablation before tumor ablation to reduce the risk of critical recurrence by blocking tumor blood flow. The aim of the present study was to clarify whether feeding artery ablation before tumor ablation can reduce the risk of critical recurrence after RFA. This study retrospectively analyzed 279 patients with primary, solitary, and hypervascular HCC ≤5 cm in diameter who were treated with RFA alone between April 2001 and August 2013. Critical recurrence was defined as intra- or extrahepatic metastasis, dissemination, or seeding that was difficult to treat radically. Of the 279 HCC patients, 157 patients were treated with conventional RFA alone, and 122 patients underwent RFA with prior feeding artery ablation. Although no significant differences were seen in the rates of local tumor progression-free survival, overall recurrence-free survival, or overall survival between a conventional RFA group and a prior feeding artery ablation group, significant differences were seen in rates of critical recurrence-free survival and cancer-specific survival (5-year, 69 Feeding artery ablation before tumor ablation may reduce the risk of critical recurrence.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Percutaneous radiofrequency ablation (RFA) is a minimally invasive and curative local treatment for hepatocellular carcinoma (HCC). However, serious concerns remain regarding critical recurrences such as metastasis, dissemination, and/or seeding due to RFA. In August 2006, we introduced selective feeding artery ablation before tumor ablation to reduce the risk of critical recurrence by blocking tumor blood flow. The aim of the present study was to clarify whether feeding artery ablation before tumor ablation can reduce the risk of critical recurrence after RFA.
METHODS
METHODS
This study retrospectively analyzed 279 patients with primary, solitary, and hypervascular HCC ≤5 cm in diameter who were treated with RFA alone between April 2001 and August 2013. Critical recurrence was defined as intra- or extrahepatic metastasis, dissemination, or seeding that was difficult to treat radically.
RESULTS
RESULTS
Of the 279 HCC patients, 157 patients were treated with conventional RFA alone, and 122 patients underwent RFA with prior feeding artery ablation. Although no significant differences were seen in the rates of local tumor progression-free survival, overall recurrence-free survival, or overall survival between a conventional RFA group and a prior feeding artery ablation group, significant differences were seen in rates of critical recurrence-free survival and cancer-specific survival (5-year, 69
CONCLUSIONS
CONCLUSIONS
Feeding artery ablation before tumor ablation may reduce the risk of critical recurrence.
Identifiants
pubmed: 33860099
doi: 10.1002/jgh3.12519
pii: JGH312519
pmc: PMC8035445
doi:
Types de publication
Journal Article
Langues
eng
Pagination
478-485Informations de copyright
© 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Biomed J. 2016 Dec;39(6):400-406
pubmed: 28043419
Am J Surg. 2004 Aug;188(2):165-7
pubmed: 15249243
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
J Gastroenterol Hepatol. 2018 Feb;33(2):347-354
pubmed: 28589639
J Vasc Interv Radiol. 2014 Nov;25(11):1691-705.e4
pubmed: 25442132
Cancer. 2010 Dec 1;116(23):5452-60
pubmed: 20672352
AJR Am J Roentgenol. 2002 Jan;178(1):53-9
pubmed: 11756087
Eur J Surg Oncol. 2009 Feb;35(2):174-9
pubmed: 18325724
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Hepatogastroenterology. 2005 Jul-Aug;52(64):1163-7
pubmed: 16001653
Liver Int. 2005 Jun;25(3):542-7
pubmed: 15910491
Cancer. 1990 Nov 15;66(10):2174-9
pubmed: 2171748
J Hepatobiliary Pancreat Surg. 2008;15(6):589-95
pubmed: 18987928
World J Gastroenterol. 2009 Jun 7;15(21):2638-43
pubmed: 19496195
Hepatology. 1997 Aug;26(2):283-7
pubmed: 9252135
Hepatol Res. 2011 Aug;41(8):738-45
pubmed: 21699637
Cancer. 2001 Mar 1;91(5):949-56
pubmed: 11251946
Hepatol Int. 2016 Mar;10(2):328-39
pubmed: 26530813
Cancer. 2002 Dec 1;95(11):2353-60
pubmed: 12436442
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Int J Hyperthermia. 2018;35(1):133-139
pubmed: 29999436
Hepatol Int. 2009 Sep;3(3):509-15
pubmed: 19669252
Surgery. 2007 Feb;141(2):196-202
pubmed: 17263976
Eur J Radiol. 2006 Sep;59(3):432-41
pubmed: 16690240